Brazil
Egypt
Europe
Hong Kong
Malaysia
Mexico
Morocco
Philippines
Saudi Arabia
South Africa
Taiwan
Thailand
Tunisia
Turkey
UAE
USA
Vietnam
Global HQ
Press Releases
Biocon Biologics / Press Releases
Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only Interchangeable Rapid-Acting Insulin Aspart in the United States
- Tue, 15-Jul-2025
- Posted by: Biocon Biologics
No Comments
Advancing Bone Health: European Commission Approves Biocon Biologics’ Denosumab Biosimilars
- Thu, 03-Jul-2025
- Posted by: Biocon Biologics
Biocon Biologics Expands Insulin Access in Malaysia
- Mon, 30-Jun-2025
- Posted by: Biocon Biologics
Biocon Biologics Receives Health Canada Approval for Yesafili™ (aflibercept); First Global Launch Scheduled for July 2025
- Fri, 27-Jun-2025
- Posted by: Biocon Biologics
Biocon Biologics Collaborates with National Cancer Society Malaysia
- Tue, 24-Jun-2025
- Posted by: Biocon Biologics
Biocon Foundation in Partnership with NCBS and BeST Cluster Launches BioWISE Program – to Empower Women in STEM
- Mon, 09-Jun-2025
- Posted by: Biocon Biologics
Biocon Q4FY25 Revenue at Rs 4,454 Cr, Up 15%** EBITDA at Rs 1,115 Cr; Up 16%; Net Profit at Rs 344 Cr, Up 153%
- Thu, 08-May-2025
- Posted by: Biocon Biologics
Biocon Biologics Secures Strong Market Access Coverage for Yesintek™ in the United States Covering 100+ Million Lives
- Mon, 05-May-2025
- Posted by: Biocon Biologics
Biocon Biologics Secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S.
- Tue, 15-Apr-2025
- Posted by: Biocon Biologics
Biocon Biologics Announces U.S. FDA Approval for Jobevne™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio
- Thu, 10-Apr-2025
- Posted by: Biocon Biologics
